This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Emergency contraception (hormonal)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Emergency contraception (EC) is used for providing safe means of preventing pregnancy following unprotected sexual intercourse or potential contraceptive failure (although the terms ‘postcoital contraception’ or ‘the morning-after pill’ are used it may be misleading hence the term emergency contraception is the preferred term) (1).

  • it is estimated that 40% of all pregnancies are unplanned out of which 60% end up as abortions
  • around 53 million abortions are being performed each year throughout the world
  • a higher rates of unplanned pregnancies and abortions are reported in the UK when compared to other European countries (2)
    • 200,000 pregnancies in the UK end in termination
    • around 90,000 teenagers become pregnant in England out of which there are 56,000 live birth
      • 2,200 are to girls aged 14 or under and 7,700 are to under 16 years age (3)
  • primary care is responsible for issuing around a third of all EC prescriptions (2)

The main methods for preventing an unwanted pregnancy following intercourse are:

  • levenorgestrel (LNG)-only postcoital contraception; this method has fewer side-effects than the previously used combined hormonal preparation (Schering PC4)
    • criteria for use (4):
      • any individual presenting for emergency contraception (EC) between 0 and 96 hours following UPSI or when regular contraception has been compromised or used incorrectly.
      • no contraindications to the medication
      • informed consent given
      • see linked item below

  • ulipristal acetate (ellaOne) (5):
    • is a selective progesterone-receptor modulator that seems to be as effective as levonorgestrel for prevention of pregnancy. Ulipristal acetate may be used up to 120h after unprotected sexual intercourse or contraceptive failure
    • orally active and taken as a single dose
    • more detailed information about ulipristal acetate is provided in the linked menu item

  • intra-uterine contraceptive device - failure rate of 0.1% and efficacious up to 5 days after unprotected intercourse. It has the advantage of being an ongoing contraceptive but may be less suited for nulliparous women who wish children in the future.

In all cases, follow up is essential and should occur 3-4 weeks after the initial treatment.

For hormonal emergency contraception, taking the first dose as soon as possible following unprotected sexual intercourse increases efficacy (6).


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.